


Amendments to the Claims



This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method for treating bladder disease in a subject, said method comprising:


administering intravesically to a subject a pharmaceutical composition comprising a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula




wherein Q is a group of the formula




R and R¹ are each independently C₁-C₄-alkyl, R₁ is thienyl, phenyl, cyclopentyl or cyclohexyl and X⁻ is a physiologically acceptable anion; (2) a compound having the formula




wherein X⁻ is a physiologically acceptable ion; (3) a compound having the formula




wherein X^- is a physiologically acceptable ion; (4) a compound having the formula




wherein R_1 is 2-thienyl or cyclopentyl, and A is 3 α -(6,7-dehydro)-tropanyl methobromide, 3 β -tropanyl methobromide, or 3 α -(N-isopropyl)-nortropanyl methobromide; (5) a compound having the formula





wherein R is an optionally halo- or hydroxyl-substituted C_{1-4} alkyl group, R^1 is a C_{1-4} alkyl group, or R and R^1 together form a C_{4-6} alkylene group; X^- is a physiologically acceptable anion, and R_1 is H, OH, CH_2OH , C_{1-4} alkyl or C_{1-4} alkoxy; (6) a compound having the formula




wherein R is an optionally halo- or hydroxy-substituted C₁₋₄ -alkyl group, R¹ is a C₁₋₄ -alkyl group, or R and R¹ together form a C₄₋₆ -alkylene group, X⁻ is a physiologically acceptable anion and R₁ is H, OH, CH₃, CH₂OH, C₁₋₄ -alkyl, or C₁₋₄ -alkoxy; (7) a compound having the formula



(8) a compound having the formula




and (9) a compound having the formula





wherein X^- is a physiologically acceptable anion.

2. (Previously Presented) The method according to claim 1, wherein the compound has the formula




wherein Q is a group of the formula




R and R¹ are each independently C₁₋₄-alkyl, R₁ is thienyl, phenyl, cyclopentyl or cyclohexyl, and X⁻ is a physiologically acceptable anion.

3. (Original) The method according to claim 2, wherein R is CH₃, C₂H₅, n-C₃H₇, or i-C₃H₇ and R¹ is CH₃.
4. (Original) The method according to claim 3, wherein R₁ is thienyl.
5. (Original) The method according to claim 2, wherein X⁻ is Br⁻ or CH₃SO₃.
6. (Original) The method according to claim 1, wherein the compound has the formula




wherein X⁻ is a physiologically acceptable ion.

7. (Withdrawn) The method according to claim 1, wherein the compound has the formula



wherein X⁻ is a physiologically acceptable ion.

8. (Withdrawn) The method according to claim 1, wherein the compound has the formula




R_1 is 2-thienyl or cyclopentyl, and A is 3 α -(6,7-dehydro)-tropanyl methobromide, 3 β -tropanyl methobromide, or 3 α -(N-isopropyl)-nortropanyl methobromide.

9. (Withdrawn) The method according to claim 8, wherein R_1 is 2-thienyl and A is 3 α -(6,7-dehydro)-tropanyl methobromide.

10. (Withdrawn) The method according to claim 8, wherein R_1 is 2-thienyl and A is 3 β -tropanyl methobromide.


11. (Withdrawn) The method according to claim 8, wherein R_1 is cyclopentyl and A is 3 α -(N-isopropyl)-nortropanyl methobromide.

12. (Withdrawn) The method according to claim 1, wherein the compound has the formula




wherein R is an optionally halo- or hydroxyl-substituted C_{1-4} alkyl group, R^1 is a C_{1-4} alkyl group, or R and R^1 together form a C_{4-6} alkylene group; X^- is a physiologically acceptable anion, and R_1 is H, OH, CH_3 , CH_2OH , C_{1-4} alkyl or C_{1-4} alkoxy.

13. (Withdrawn) The method according to claim 12, wherein X^- is bromide.
14. (Withdrawn) The method according to claim 12, wherein R_1 is OH, CH_3 , or CH_2OH .
15. (Withdrawn) The method according to claim 12, wherein R is methyl and R^1 is methyl, ethyl, n-propyl or i-propyl.
16. (Withdrawn) The method according to claim 1, wherein the compound has the formula




wherein R is an optionally halo- or hydroxy-substituted C_{1-4} -alkyl group, R^1 is a C_{1-4} -alkyl group, or R and R^1 together form a C_{4-6} -alkylene group, X^- is a physiologically acceptable anion and R_1 is H, OH, CH_2OH , C_{1-4} -alkyl, or C_{1-4} -alkoxy.


17. (Withdrawn) The method according to claim 16, wherein X^- is bromide.
18. (Withdrawn) The method according to claim 16, wherein R_1 is OH, CH_3 , or CH_2OH .
19. (Withdrawn) The method according to claim 16, wherein R is methyl and R^1 is methyl, ethyl, n-propyl or i-propyl.
20. (Withdrawn-- Currently Amended) The method according to claim 1, wherein the compound has the formula



21. (Withdrawn) The method according to claim 1, wherein the compound has the formula



22. (Currently Amended) The method according to claim 1, wherein the compound has the formula



wherein X^- is a physiologically acceptable anion.

23. (Original) The method according to claim 22, wherein X^- is a bromide.
24. (Previously Presented) The method according to claim 1, wherein the pharmaceutical composition is formulated to have a prolonged duration of action.
25. (Previously Presented) The method according to claim 24, wherein the prolonged duration of action is at least about three weeks.
26. (Currently Amended) The method according to claim 1, wherein the pharmaceutical composition further comprises an additive selected from the group consisting of carboxymethyl celluloses, glycosaminoglycans, pentosan polysulfate, and heparin, ~~and heparin-like compounds.~~
27. (Previously Presented) The method according to claim 1, wherein the subject has a condition selected from the group consisting of urge incontinence, cystitis, bladder dysfunction of multiple sclerosis, benign prostatic hyperplasia, myelomeningocele, spinal cord injury, dementia where antimuscarinic medications are contraindicated, parkinsonism, and inability to tolerate systemic effects of antimuscarinic medications.